Patrick Ott
Clinical Director of Center for Immuno-Oncology; IND Holder of NeoVax · Mass General Brigham
Credentials: · · · ·
History
- Present
Center for Immuno-oncology; IND holder of NeoVax · Mass General Brigham
- Present
Melanoma Disease Center · Mass General Brigham
- Present
Research
An immunogenic personal neoantigen vaccine for patients with melanoma
Nature · 2017 · First of 40 authors · 2,312 citations
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma
New England Journal of Medicine · 2015 · 2,283 citations
Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy
Science · 2018 · 1,911 citations
49 papers
- EB
29 papers
22 papers
20 papers
- JL
18 papers · 3 as a fellow
13 papers
13 papers
11 papers
Grants
- 2018–2031
National Cancer Institute · R01
Contact PI · $3.8M · Dana-Farber Cancer Inst
Clinical trials
- 2022–2030
NeoVax + CDX-301 and Nivolumab or Pembrolizumab in Melanoma
Principal investigator · Active not recruiting · Phase 1
Dana-Farber Cancer Institute
- 2020–2028
Neoantigen Vaccine Plus Locally Administered Ipilimumab and Systemic Nivolumab in Advanced Melanoma
Principal investigator · Active not recruiting · Phase 1
Dana-Farber Cancer Institute
- 2019–2030
NeoVax Plus Ipilimumab in Renal Cell Carcinoma
Principal investigator · Active not recruiting · Phase 1
Patrick Ott, MD, PhD
- 2014–2020
Principal investigator · Completed · Phase 1
F. Stephen Hodi, MD